Angels Santé
VC Fund
Puteaux, France
Angels Santé is a VC fund in Puteaux focused on Health Care and Biotechnology. Angels Santé is the leading French Business Angel Network solely dedicated to Healthcare investments.
- Total investments:
- 37
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Angels Santé invests in
Stages Angels Santé invests in
Countries Angels Santé invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $1.1M–$4.6M
- Angel
- $658k–$1.3M
Investment Focus
Industry
- Health Care 15 (41%)
- Biotechnology 12 (32%)
- Medical Device 6 (16%)
- Medical 5 (14%)
- Life Science 4 (11%)
Stage
- Seed 22 (59%)
- Funding Round 4 (11%)
- Angel 2 (5%)
- Pre-Seed 2 (5%)
- Series A 2 (5%)
Country
- France 28 (76%)
- India 1 (3%)
- United States 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Guy-Charles Fanneau de la Horie
Co-founder
|
Co-founder | Total investments: 0 | Find email | |
|
Patrick squiban
Executive
|
Executive | Total investments: 1 | Find email | |
|
Pierre-Emmanuel Aubert
Co-Founder and member of the board
|
Co-Founder and member of the board | Total investments: 0 | Find email | |
|
Stéphane Loze
Administrator – Partnerships Manager – Treasurer
|
Administrator – Partnerships Manager – Treasurer | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Kimialys develops and sells proprietary and patented surface chemistry for biosensors, increasing their sensitivity and specificity to deliver reliable, rapid, and cost-effective diagnostic tests. It was founded in 2020 by Cyril Gilbert and Claude Nogues in Paris, Ile-de-France, France. | $4.2M / Seed / Dec 05, 2025 | |
|
|
SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules. | $2.3M / Seed / Oct 01, 2025 | |
|
|
StemInov is a biotechnology company that focuses on the development of stem cell therapies for inflammatory diseases. The company's primary focus is on critical care, specifically septic shock and Acute Respiratory Distress Syndrome (ARDS). StemInov's approach is based on robust preclinical data and widely accepted safety measures. Thecompany is developing an off-the-shelf and allogenic cell therapy. StemInov is also working on a drug-based therapy using mesenchymatous stem cells from Wharton's jelly (WJ-MSC). | $12.4M / Series A / Sep 25, 2025 | |
|
|
AUSTRAL Dx is developing a new imaging technique based on airborne ultrasounds in order to map the vibrations coming from the lungs. The company was founded in 2021 and is based in Paris. | $1.1M / Seed / Jul 24, 2025 | |
|
|
Ensweet is a telemedicine platform intended to offer telerehabilitation services to patients. They offer equipment so that everyone can exercise whenever possible, enabling patients to have accessible rehabilitation. | $3.4M / Seed / May 20, 2025 | |
|
|
MB Therapeutics is a pharmaceutical firm that provides patient-centric solutions for developing and producing tailored medicines. | $2.1M / Seed / Feb 24, 2025 | |
|
|
Sirius NeoSight is a biotech and pharmaceutical company that detects subclinical neo-cancers and provide treatment for it. | $4.6M / Seed / Feb 04, 2025 | |
|
|
Hephaistos Pharma is a developing weapons firm. They provide services for oncology, immunotherapy, and cancer. An online inquiry form is available on the company's website. | $4.9M / Seed / Jan 23, 2024 | |
|
|
SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules. | $1.3M / Seed / Sep 26, 2023 | |
|
|
Abcely is a biotech firm that is working on a novel anti-cancer medication. | $2.6M / Seed / Sep 21, 2023 | |
| See all 37 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Angels Santé invest in?
Angels Santé invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed and Funding Round stage. Most of the 37 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Angels Santé's check size?
Angels Santé typically joins rounds of $1.1M–$4.6M at Seed and $658k–$1.3M at Angel. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Angels Santé participates in.
How do I contact Angels Santé?
Public channels for Angels Santé include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Angels Santé?
The team at Angels Santé includes Guy-Charles Fanneau de la Horie (Co-founder), Patrick squiban (Executive) and Pierre-Emmanuel Aubert (Co-Founder and member of the board). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!